| Company | Value | Change | %Change |
|---|
US formulation sales for Zydus Life during the quarter stood at $285 million, which is a growth of 29% on a year-on-year basis. The figure is also higher than the $270 million estimate.
The US contributes nearly 47% to Zydus Life’s overall topline.
Revenue during the quarter grew by 17% for the company to ₹5,269 crore, while its net profit stood at ₹1,023 crore from ₹789 crore last year, implying a growth of 30%.
The company’s profitability was aided by a surge in its forex gain, which stood at ₹183 crore during the quarter, compared to a gain of ₹21 crore during the same quarter last year.
Zydus Life’s Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) stood at ₹1,387 crore at the end of the December quarter. The company had reported an EBITDA of ₹1,102 crore in the base quarter.
EBITDA margin expanded by nearly 200 basis points to 26.3% from 24.5% last year.
The company’s net-debt-to-equity ratio as of December 13 stood at a negative 0.14 times, compared to a negative 0.47 times at the end of the December quarter last year.
The management of Zydus Life also reiterated that they are on track to achieve their financial year 2025 goal of double-digit growth across their key businesses, coupled with improved profitability.
“Our robust portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in international markets position us well for future growth,” Zydus Life Managing Director Sharvil Patel said.
Shares of Zydus Life have declined to the lowest point of the day, currently trading 1.5% lower at ₹959.15.
First Published: Feb 5, 2025 12:51 PM IST
